F2 and COVID-19: Hospitalized patients infected with coronavirus disease 2019 (COVID-19) were reported to suffer from a hypercoagulable state, characterized by changes in coagulation tests (elevated D-dimer, prolonged prothrombin time [PT], activated partial thromboplastin time (aPTT), and/or low fibrinogen levels) (1-3) and higher levels of C-reactive protein (CRP), lactate dehydrogenase (LDH), and transaminases (4).